日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

[Expression of Concern] Establishment and evaluation of a new highly metastatic tumor cell line 5a‑D‑Luc‑ZsGreen expressing both luciferase and green fluorescent protein

【关注事项】建立和评估一种新的高转移性肿瘤细胞系 5a-D-Luc-ZsGreen,该细胞系同时表达荧光素酶和绿色荧光蛋白

Sudo, Hitomi; Tsuji, Atsushi B; Sugyo, Aya; Takuwa, Hiroyuki; Masamoto, Kazuto; Tomita, Yutaka; Suzuki, Norihiro; Imamura, Takeshi; Koizumi, Mitsuru; Saga, Tsuneo

(191)Pt-labeled trithiol-Hoechst-PSMA: preliminary evaluation of conjugates designed for delivery to genomic DNA of PSMA-positive cancers

(191)Pt标记的三硫醇-Hoechst-PSMA:用于递送至PSMA阳性癌症基因组DNA的缀合物的初步评估

Obata, Honoka; Tsuji, Atsushi B; Feng, Yutian; Zheng, Yongxiang; Sugyo, Aya; Sudo, Hitomi; Kajiwara, Chie; Minegishi, Katsuyuki; Zhang, Ming-Rong; Zalutsky, Michael R

Prediction of tumour hypoxia status from the washout of positron emitters in beam-monitoring PET: carbon-ion irradiation to tumour rat models

利用正电子发射体清除率在束流监测PET中预测肿瘤乏氧状态:碳离子照射肿瘤大鼠模型

Toramatsu, Chie; Wakizaka, Hidekatsu; Tashima, Hideaki; Sudo, Hitomi; Akamatsu, Go; Ishikawa, Taiyo; Kang, Han Gyu; Seki, Chie; Kanno, Iwao; Yamaya, Taiga

The tyrosine kinase inhibitor nintedanib enhances the efficacy of 90 Y-labeled B5209B radioimmunotherapy targeting ROBO1 without increased toxicity in small-cell lung cancer xenograft mice

酪氨酸激酶抑制剂尼达尼布可增强靶向 ROBO1 的 90Y 标记 B5209B 放射免疫疗法在小细胞肺癌异种移植小鼠中的疗效,且不增加毒性。

Fujiwara, Kentaro; Tsuji, Atsushi B; Sudo, Hitomi; Sugyo, Aya; Hamakubo, Takao; Higashi, Tatsuya

Head-to-head comparison of three chelates reveals DOTAGA promising for (225) Ac labeling of anti-FZD10 antibody OTSA101

三种螯合物的直接比较表明,DOTAGA有望用于抗FZD10抗体OTSA101的(225)Ac标记。

Sudo, Hitomi; Tsuji, Atsushi B; Sugyo, Aya; Harada, Yosuke; Nagayama, Satoshi; Katagiri, Toyomasa; Nakamura, Yusuke; Higashi, Tatsuya

FZD10-targeted α-radioimmunotherapy with (225) Ac-labeled OTSA101 achieves complete remission in a synovial sarcoma model

使用 (225)Ac 标记的 OTSA101 进行 FZD10 靶向 α 放射免疫疗法,可在滑膜肉瘤模型中实现完全缓解。

Sudo, Hitomi; Tsuji, Atsushi B; Sugyo, Aya; Harada, Yosuke; Nagayama, Satoshi; Katagiri, Toyomasa; Nakamura, Yusuke; Higashi, Tatsuya

In vivo validation of the switch antibody concept: SPECT/CT imaging of the anti-CD137 switch antibody Sta-MB shows high uptake in tumors but low uptake in normal organs in human CD137 knock-in mice

体内验证转换抗体概念:SPECT/CT成像显示,抗CD137转换抗体Sta-MB在人CD137敲入小鼠的肿瘤中摄取量高,而在正常器官中摄取量低。

Sugyo, Aya; Tsuji, Atsushi B; Sudo, Hitomi; Narita, Yoshinori; Taniguchi, Kenji; Nemoto, Takayuki; Isomura, Fumihisa; Awaya, Norihiro; Kamata-Sakurai, Mika; Higashi, Tatsuya

The natural sulfoglycolipid derivative SQAP improves the therapeutic efficacy of tissue factor-targeted radioimmunotherapy in the stroma-rich pancreatic cancer model BxPC-3

天然硫糖脂衍生物SQAP可提高组织因子靶向放射免疫疗法在富含基质的胰腺癌模型BxPC-3中的治疗效果。

Takakusagi, Yoichi; Sugyo, Aya; Tsuji, Atsushi B; Sudo, Hitomi; Yasunaga, Masahiro; Matsumura, Yasuhiro; Sugawara, Fumio; Sakaguchi, Kengo; Higashi, Tatsuya

Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma

利用新型抗体NZ-16进行靶向足蛋白的α放射免疫疗法治疗恶性间皮瘤的临床前评估

Sudo, Hitomi; Tsuji, Atsushi B; Sugyo, Aya; Kaneko, Mika K; Kato, Yukinari; Nagatsu, Kotaro; Suzuki, Hisashi; Higashi, Tatsuya

Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression

放射性标记的人单克隆抗体067-213具有无创定量检测CD73表达的潜力

Sudo, Hitomi; Tsuji, Atsushi B; Sugyo, Aya; Kurosawa, Gene; Kurosawa, Yoshikazu; Alexander, David; Tsuda, Hiroyuki; Saga, Tsuneo; Higashi, Tatsuya